fluphenazine has been researched along with caffeine in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (33.33) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Creveling, CR; Daly, JW; Lewandowski, GA; McNeal, ET | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Caradonna, NP; Hallifax, D; Houston, JB; Turlizzi, E; Zanelli, U | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cho, YS; Hwang, EM; Jung, SY; Lim, SM; Min, SJ; Pae, AN; Park, KD; Viswanath, AN | 1 |
| Ashoori, F; Takai, A; Tomita, T | 1 |
| Castellani, S | 1 |
| Caroff, S; Gerber, JC; Rosenberg, H | 1 |
| Kann, ML; Serres, C | 1 |
| Campos, E; Chayet, L; Collados, L; García, L; Kettlun, AM; Traverso-Cori, A; Valenzuela, MA | 1 |
| Baroth, V; Breitkreutz, J; Gröning, R; Müller, RS | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
1 review(s) available for fluphenazine and caffeine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
14 other study(ies) available for fluphenazine and caffeine
| Article | Year |
|---|---|
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthetics, Local; Animals; Batrachotoxins; Calcium Channel Blockers; Cyclic AMP; Guinea Pigs; Histamine H1 Antagonists; In Vitro Techniques; Ion Channels; Neurotoxins; Sodium; Tranquilizing Agents; Tritium | 1985 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
Topics: Cell Line, Tumor; Cryopreservation; Female; Hepatocytes; Humans; Male; Metabolic Clearance Rate; Pharmaceutical Preparations; Predictive Value of Tests | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Identification of the first in silico-designed TREK1 antagonists that block channel currents dose dependently.
Topics: Animals; Computer Simulation; Crystallography, X-Ray; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Mice; Mice, Knockout; Molecular Docking Simulation; Potassium Channels, Tandem Pore Domain | 2016 |
The response of non-pregnant rat myometrium to oxytocin in Ca-free solution.
Topics: Animals; Caffeine; Calcium; Chlorpromazine; Female; Fluphenazine; In Vitro Techniques; Myometrium; Oxytocin; Rats; Rats, Inbred Strains; Sulfonamides; Trifluoperazine; Uterine Contraction | 1985 |
Catatonia associated with phenylpropanolamine overdose and fluphenazine treatment: case report.
Topics: Benztropine; Caffeine; Catatonia; Fluphenazine; Humans; Male; Middle Aged; Phenylpropanolamine; Receptors, Dopamine | 1985 |
Neuroleptic malignant syndrome and malignant hyperthermia.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Caffeine; Fever; Fluphenazine; Halothane; Humans; Muscle Contraction; Syndrome | 1983 |
Motility induction in hamster spermatozoa from caput epididymidis: effects of forward motility protein (FMP) and calmodulin inhibitor.
Topics: Animals; Caffeine; Cricetinae; Epididymis; Fluphenazine; Male; Microscopy, Phase-Contrast; Proteins; Sperm Agglutination; Sperm Motility; Spermatozoa | 1984 |
Human placental ecto-enzymes: studies on the plasma membrane anchorage and effect of inhibitors of ATP-metabolizing enzymes.
Topics: 5'-Nucleotidase; Alkaline Phosphatase; Amitriptyline; Apyrase; Caffeine; Cell Membrane; Endopeptidases; Enzyme Inhibitors; Female; Fluphenazine; Glycosylphosphatidylinositols; Humans; Lidocaine; Microvilli; Nucleotides; Phosphatidylinositol Diacylglycerol-Lyase; Phospholipase D; Placenta; Type C Phospholipases | 1997 |
Nanoparticles in plant extracts: influence of drugs on the formation of nanoparticles and precipitates in black tea infusions.
Topics: Caffeine; Chemical Precipitation; Fluphenazine; Humans; Microscopy, Electron, Scanning; Molecular Structure; Particle Size; Plant Extracts; Promethazine; Spectrum Analysis; Tea | 2002 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |